100 related articles for article (PubMed ID: 23494205)
1. Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab.
So CC; Choi WW; Kwong YL
Ann Hematol; 2013 Oct; 92(10):1425-6. PubMed ID: 23494205
[No Abstract] [Full Text] [Related]
2. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
Ohno H
Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
[No Abstract] [Full Text] [Related]
3. Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia.
Pantelidou D; Tsatalas C; Margaritis D; Kaloutsi V; Spanoudakis E; Bourikas G
Hematol J; 2004; 5(6):546-7. PubMed ID: 15570303
[No Abstract] [Full Text] [Related]
4. Rituximab in CD20 positive multiple myeloma.
Bergua JM; Cabrera C; Arteta EG; Prieto J
Leukemia; 2008 May; 22(5):1082-3. PubMed ID: 17972949
[No Abstract] [Full Text] [Related]
5. Reply to 'Rituximab activity in CD20-positive multiple myeloma'.
Gozzetti A; Fabbri A; Lazzi S; Bocchia M; Lauria F
Leukemia; 2008 May; 22(5):1083; author reply 1083-4. PubMed ID: 17972948
[No Abstract] [Full Text] [Related]
6. Selective loss of lymphoid component simulating myeloma in lymphoplasmacytic lymphoma treated with rituximab.
O'Connor SR; Rana SK
Br J Haematol; 2013 May; 161(4):460. PubMed ID: 23530469
[No Abstract] [Full Text] [Related]
7. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide.
Gupta RK; Ezeonyeji AN; Thomas AS; Scully MA; Ehrenstein MR; Isenberg DA
Lupus; 2011 Dec; 20(14):1547-50. PubMed ID: 21993386
[TBL] [Abstract][Full Text] [Related]
8. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
[No Abstract] [Full Text] [Related]
9. Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient.
Scaramucci L; Niscola P; Ales M; Giovannini M; Tendas A; Cupelli L; Siniscalchi A; Piccioni D; Dentamaro T; Perrotti A; de Fabritiis P
Int J Hematol; 2008 Oct; 88(3):343-344. PubMed ID: 18807120
[No Abstract] [Full Text] [Related]
10. Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.
Del Principe MI; Cefalo M; Buccisano F; Anemona L; Sarlo C; Di Caprio L; De Santis G; Giacobbi E; Maurillo L; Postorino M; Del Poeta G; Amadori S; Venditti A
Ann Hematol; 2014 Sep; 93(9):1611-2. PubMed ID: 24452366
[No Abstract] [Full Text] [Related]
11. Rituximab in CD20 positive multiple myeloma.
Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
[No Abstract] [Full Text] [Related]
12. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.
Zecca M; De Stefano P; Nobili B; Locatelli F
Blood; 2001 Jun; 97(12):3995-7. PubMed ID: 11389047
[TBL] [Abstract][Full Text] [Related]
13. CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
Xu X; Broome EH; Rashidi HH; South ST; Dell'aquila ML; Wang HY
Int J Clin Exp Pathol; 2010 Sep; 3(8):798-807. PubMed ID: 21151394
[TBL] [Abstract][Full Text] [Related]
14. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia.
Mandreoli M; Finelli C; Lopez A; Ascani S; Vianelli N; Baccarani M; Santoro A
Am J Kidney Dis; 2004 Oct; 44(4):757-61. PubMed ID: 15384028
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
[TBL] [Abstract][Full Text] [Related]
16. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia.
D'Arena G; Vigliotti ML; Dell'Olio M; Villa MR; Mantuano S; Scalzulli PR; La Sala A; Abbadessa A; Mastrullo L; Cascavilla N
Eur J Haematol; 2009 Mar; 82(3):235-9. PubMed ID: 19067738
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation.
Sorà F; De Matteis S; Piccirillo N; Chiusolo P; Laurenti L; Putzulu R; Leone G; Sica S
Transfusion; 2005 Apr; 45(4):643-5. PubMed ID: 15819690
[No Abstract] [Full Text] [Related]
18. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
Leiper K; Martin K; Ellis A; Subramanian S; Watson AJ; Christmas SE; Howarth D; Campbell F; Rhodes JM
Gut; 2011 Nov; 60(11):1520-6. PubMed ID: 21471566
[TBL] [Abstract][Full Text] [Related]
19. Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab.
Benson DM; Smith MK; Krugh D; Devine SM
Bone Marrow Transplant; 2008 Mar; 41(6):595-6. PubMed ID: 18037934
[No Abstract] [Full Text] [Related]
20. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment.
Auner HW; Wölfler A; Beham-Schmid C; Strunk D; Linkesch W; Sill H
Br J Haematol; 2002 Mar; 116(3):727-8. PubMed ID: 11879264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
